A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop
Authors:
Open Access
- 1 January 2018
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 8 (5) , 1256-1269
Abstract
Purpose: MicroRNA-630 plays dual roles in apoptosis and drug resistance in human cancers. However, the role of miR-630 in resistance to tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma remains to be elucidated.Keywords
This publication has 32 references indexed in Scilit:
- MiR-630 inhibits invasion and metastasis in esophageal squamous cell carcinomaActa Biochimica et Biophysica Sinica, 2016
- miR-630 functions as a tumor oncogene in renal cell carcinomaArchives of Medical Science, 2016
- Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival.2014
- Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expressionOncogene, 2013
- Upregulation of miR-150* and miR-630 Induces Apoptosis in Pancreatic Cancer Cells by Targeting IGF-1RPLOS ONE, 2013
- Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer CellsMolecular Cancer Therapeutics, 2012
- Phospho-ΔNp63α is a key regulator of the cisplatin-induced microRNAome in cancer cellsCell Death & Differentiation, 2011
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFRNature Genetics, 2005
- Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad.2003